Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Pantoloc M | Pantoprazole magnesium | Gastric acid secretion, reduction of | List in a similar manner to other drugs in class | Complete | ||
Trelstar | Triptorelin pamoate | Cancer, prostate | List in a similar manner to other drugs in class | Complete | ||
Remodulin | Treprostinil sodium | Pulmonary arterial hypertension (NYHA Class III and IV patients) | List with clinical criteria and/or conditions | Complete | ||
Sutent | Sunitinib | Gastrointestinal stromal tumour (GIST) | List with clinical criteria and/or conditions | Complete | ||
Vesicare | Solifenacin succinate | Bladder, overactive | Do not list | Complete | ||
Nexavar | Sorafenib tablets | Cancer, Renal cell carcinoma | Do not list | Complete | ||
Prezista | Darunavir | HIV infection | List with clinical criteria and/or conditions | Complete | ||
Azilect | Rasagiline mesylate | Parkinson's disease | Do not list | Complete | ||
Alvesco | Ciclesonide | asthma | List | Complete | ||
Denavir | Penciclovir | Herpes labialis (cold sores) | Do not list | Complete |